FDA approves study of STAAR Surgical’s lenses for myopia, astigmatism

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has approved a human clinical study of the EVO/EVO+ Visian ICL for myopia and the EVO/EVO+ Visian toric ICL for myopia with astigmatism, STAAR Surgical announced in a press release.

The study will include 300 subjects with a primary endpoint at 6 months’ follow-up, the release said.

“STAAR looks forward to the next step in moving our trial forward, gaining institutional review board approval and initiating the EVO/EVO+ clinical trial as soon as possible, which we anticipate will be during the first quarter of calendar 2020,” Caren Mason, president and CEO of STAAR Surgical, said in the release.